Fig. 5From: Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysisData points with different values of H using targeted projection pursuit. a EGFR mutant-gefitinib complexes. b EGFR mutant-erlotinib complexes. Each point stands for an EGFR mutant-TKI complex with high (red) moderate (blue) or low (green) sensitivity to the corresponding TKIBack to article page